568 related articles for article (PubMed ID: 31076001)
21. Targeting Lipid Metabolism in Liver Cancer.
Alannan M; Fayyad-Kazan H; Trézéguet V; Merched A
Biochemistry; 2020 Oct; 59(41):3951-3964. PubMed ID: 32930581
[TBL] [Abstract][Full Text] [Related]
22. Dysregulated signaling hubs of liver lipid metabolism reveal hepatocellular carcinoma pathogenesis.
Lee S; Mardinoglu A; Zhang C; Lee D; Nielsen J
Nucleic Acids Res; 2016 Jul; 44(12):5529-39. PubMed ID: 27216817
[TBL] [Abstract][Full Text] [Related]
23. Role of stearoyl-CoA desaturase-1 in skeletal muscle function and metabolism.
Stamatikos AD; Paton CM
Am J Physiol Endocrinol Metab; 2013 Oct; 305(7):E767-75. PubMed ID: 23941875
[TBL] [Abstract][Full Text] [Related]
24. Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells.
Cao D; Song X; Che L; Li X; Pilo MG; Vidili G; Porcu A; Solinas A; Cigliano A; Pes GM; Ribback S; Dombrowski F; Chen X; Li L; Calvisi DF
Liver Int; 2017 Jan; 37(1):80-89. PubMed ID: 27264722
[TBL] [Abstract][Full Text] [Related]
25. Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation.
Ma MKF; Lau EYT; Leung DHW; Lo J; Ho NPY; Cheng LKW; Ma S; Lin CH; Copland JA; Ding J; Lo RCL; Ng IOL; Lee TKW
J Hepatol; 2017 Nov; 67(5):979-990. PubMed ID: 28647567
[TBL] [Abstract][Full Text] [Related]
26. Integrative transcriptome analysis of liver cancer profiles identifies upstream regulators and clinical significance of ACSM3 gene expression.
Gopal R; Selvarasu K; Pandian PP; Ganesan K
Cell Oncol (Dordr); 2017 Jun; 40(3):219-233. PubMed ID: 28390038
[TBL] [Abstract][Full Text] [Related]
27. Relationships between hepatic stearoyl-CoA desaturase-1 activity and mRNA expression with liver fat content in humans.
Peter A; Cegan A; Wagner S; Elcnerova M; Königsrainer A; Königsrainer I; Häring HU; Schleicher ED; Stefan N
Am J Physiol Endocrinol Metab; 2011 Feb; 300(2):E321-6. PubMed ID: 21045174
[TBL] [Abstract][Full Text] [Related]
28. Caffeic Acid Expands Anti-Tumor Effect of Metformin in Human Metastatic Cervical Carcinoma HTB-34 Cells: Implications of AMPK Activation and Impairment of Fatty Acids De Novo Biosynthesis.
Tyszka-Czochara M; Konieczny P; Majka M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230778
[TBL] [Abstract][Full Text] [Related]
29. Regulation of energy metabolism by long-chain fatty acids.
Nakamura MT; Yudell BE; Loor JJ
Prog Lipid Res; 2014 Jan; 53():124-44. PubMed ID: 24362249
[TBL] [Abstract][Full Text] [Related]
30. A biphasic response pattern of lipid metabolomics in the stage progression of hepatitis B virus X tumorigenesis.
Teng CF; Hsieh WC; Yang CW; Su HM; Tsai TF; Sung WC; Huang W; Su IJ
Mol Carcinog; 2016 Jan; 55(1):105-14. PubMed ID: 25594851
[TBL] [Abstract][Full Text] [Related]
31. Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials.
Noonan A; Pawlik TM
Expert Opin Investig Drugs; 2019 Nov; 28(11):941-949. PubMed ID: 31590579
[No Abstract] [Full Text] [Related]
32. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.
Che L; Chi W; Qiao Y; Zhang J; Song X; Liu Y; Li L; Jia J; Pilo MG; Wang J; Cigliano A; Ma Z; Kuang W; Tang Z; Zhang Z; Shui G; Ribback S; Dombrowski F; Evert M; Pascale RM; Cossu C; Pes GM; Osborne TF; Calvisi DF; Chen X; Chen L
Gut; 2020 Jan; 69(1):177-186. PubMed ID: 30954949
[TBL] [Abstract][Full Text] [Related]
33. MiR-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSL1) mRNA.
Cui M; Wang Y; Sun B; Xiao Z; Ye L; Zhang X
Biochem Biophys Res Commun; 2014 Feb; 444(2):270-5. PubMed ID: 24462768
[TBL] [Abstract][Full Text] [Related]
34. Survivin in survival of hepatocellular carcinoma.
Su C
Cancer Lett; 2016 Sep; 379(2):184-90. PubMed ID: 26118774
[TBL] [Abstract][Full Text] [Related]
35. Fatty acid metabolic enzyme acyl-CoA thioesterase 8 promotes the development of hepatocellular carcinoma.
Hung YH; Chan YS; Chang YS; Lee KT; Hsu HP; Yen MC; Chen WC; Wang CY; Lai MD
Oncol Rep; 2014 Jun; 31(6):2797-803. PubMed ID: 24788990
[TBL] [Abstract][Full Text] [Related]
36. 6PGD inhibition sensitizes hepatocellular carcinoma to chemotherapy via AMPK activation and metabolic reprogramming.
Chen H; Wu D; Bao L; Yin T; Lei D; Yu J; Tong X
Biomed Pharmacother; 2019 Mar; 111():1353-1358. PubMed ID: 30841449
[TBL] [Abstract][Full Text] [Related]
37. Novel therapeutic targets and predictive markers for hepatocellular carcinoma.
Chan SL; Chan AW; Yeo W
Expert Opin Ther Targets; 2015 Jul; 19(7):973-83. PubMed ID: 25910512
[TBL] [Abstract][Full Text] [Related]
38. Molecular Mechanisms and Targets of Therapy for Hepatocellular Carcinoma.
Klungboonkrong V; Das D; McLennan G
J Vasc Interv Radiol; 2017 Jul; 28(7):949-955. PubMed ID: 28416267
[TBL] [Abstract][Full Text] [Related]
39. Cancer Metabolism as a Mechanism of Treatment Resistance and Potential Therapeutic Target in Hepatocellular Carcinoma.
Lee M; Ko H; Yun M
Yonsei Med J; 2018 Dec; 59(10):1143-1149. PubMed ID: 30450847
[TBL] [Abstract][Full Text] [Related]
40. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression.
Hilvo M; Denkert C; Lehtinen L; Müller B; Brockmöller S; Seppänen-Laakso T; Budczies J; Bucher E; Yetukuri L; Castillo S; Berg E; Nygren H; Sysi-Aho M; Griffin JL; Fiehn O; Loibl S; Richter-Ehrenstein C; Radke C; Hyötyläinen T; Kallioniemi O; Iljin K; Oresic M
Cancer Res; 2011 May; 71(9):3236-45. PubMed ID: 21415164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
